Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

Category	Detail
Condition	Acquired and congenital hematopoietic disorders, immune system disorders, metabolic disorders
Key Mechanisms	Hematopoietic stem cell transplantation (HSCT) using various donor types and stem cell sources
Target Population	Patients requiring HSCT for hematopoietic, immune, or metabolic disorders across Europe and affiliated countries
Care Setting	Specialized transplant centers across Europe and affiliated countries

In 2013, 34,809 patients received first HSCT; 43% allogeneic and 57% autologous.
Increased use of haploidentical (mismatched family) donors observed, with decreased cord blood transplants.
Survey included data from 658 teams in 48 countries with a 96% return rate, enabling trend analysis over 20 years.

HSCT indicated for acquired and congenital hematopoietic disorders, immune system disorders, and metabolic enzyme replacement.

Selection of donor type includes HLA-identical siblings, matched unrelated donors, haploidentical donors, and cord blood.
Use of haploidentical donors is increasing, while cord blood transplants are decreasing.
Multiple and retransplants are performed based on relapse, rejection, or planned sequential protocols.

Data collection and validation through national registries, EBMT database, and quality control measures.
Monitoring transplant rates per 10 million inhabitants to assess trends and technology adoption.

Risks include graft rejection, relapse, and complications requiring retransplantation or donor lymphocyte infusions (DLIs).

34,809 first transplant patients in 2013; adults and pediatric patients across Europe and affiliated countries.

Allogeneic HSCT accounts for 43% and autologous HSCT for 57% of first transplants; increasing trend in allogeneic HSCT and haploidentical donor use.

Comprehensive data reporting by transplant centers to monitor trends and outcomes.
Utilization of multiple donor types tailored to patient needs and availability.
Incorporation of novel cellular therapies and reduced intensity conditioning protocols.
Quality control through cross-validation with multiple registries and databases.

Clinical Scorecard: Trends in Hematopoietic Stem Cell Transplantation in Europe: Increased Use of Haploidentical Donors and Decreased Cord Blood Transplants in 2013